A simple microplate virus inhibition assay which measures the levels of acyclovir in plasma and urine samples from patients was developed. The assay is based upon the inhibition of the cytopathic effect of herpes simplex virus type 1 on human fibroblast cells. The extent of inhibition of virus cytopathic effect, caused by dilutions of samples from patients, allowed determination of acyclovir concentrations to be made. The assay, which measured biological activity, could detect acyclovir levels of -1.0 ,uM. Peak and valley levels measured in plasma samples from two patients were comparable to values obtained by radioimmunoassay. The assay is simple, rapid, and quantitative, and it can be adapted to routine use for a large number of specimens. Acyclovir (9-(2-hydroxyethoxymethyl) -guanine [ACV]) has potent in vitro antiviral activity against herpes simplex virus type 1 (HSV-1) and type 2 and varicella-zoster virus (1, 3, 4, 13) . ACV is phosphorylated by HSV-induced thymidine kinase and preferentially inhibits virus-induced deoxyribonucleic acid polymerase (5, 7). This selective mechanism of action on a virus-specific function makes the compound more active in virus-infected cells with a low potential for toxicity to the host.
activity against herpes simplex virus type 1 (HSV-1) and type 2 and varicella-zoster virus (1, 3, 4, 13) . ACV is phosphorylated by HSV-induced thymidine kinase and preferentially inhibits virus-induced deoxyribonucleic acid polymerase (5, 7) . This selective mechanism of action on a virus-specific function makes the compound more active in virus-infected cells with a low potential for toxicity to the host.
ACV has been reported to be effective in treatment of experimental herpes simplex infections in animal models and also in topical therapy of human HSV ocular infections (6, 9, 10, 11, 13) . Clinical trials are now under way to determine the potential of parenteral ACV for treatment ofhuman infections caused by herpesgroup viruses.
Determination of the pharmacokinetics of ACV in patients is important in establishing both therapeutic and safe dosages and correlating these results with clinical outcome.
In this paper, we describe a virus inhibition assay which is simple, rapid, quantitative, and capable of measuring the biological activity of ACV in plasma and urine samples from patients receiving parenteral ACV.
growth medium containing Eagle basal medium with 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, and 10% fetal bovine serum. Maintenance medium consisting of BME, antibiotics, and 2% fetal bovine serum was used for virus-infected cultures.
Virus. HSV-1 Linderman was obtained from Andr6
Nahmias (Emory University, Atlanta, Ga. plates. This assay is based upon the measurement ofthe highest dilution of a patient's sample that will inhibit the cytopathic effect of HSV-1. This value is compared with the virus inhibition endpoint of known standard quantities of acyclovir.
To test the susceptibility and reproducibility of this assay in comparison with those of the plaque assay, we first determined standard dilution endpoints for ACV prepared in maintenance medium. CCL-54 cells grown in microculture were infected with HSV-1, and maintenance medium contSining ACV concentrations of 200 uM was added to the first well of each of two rows; serial twofold dilutions were then made in the plates. The plates were incubated and scored for CPE as described above. The results of five initial experiments are tabulated in Table 1 . The endpoints of the dilution with 1+ CPE occurred reproducibly at 1.25 and 0.625 uM acyclovir. These values remained constant in this assay and set the lower limit of susceptibility at approximately 1 AM.
To determine the accuracy of the microplate virus inhibition assay over a wide range of ACV concentrations and to construct a standard curve, we performed the assay with concentrations of ACV ranging from 0 to 200 ,uM diluted in maintenance medium. The reciprocal of the endpoint is plotted as a function of the concentration of ACV in Fig. 2 for triplicate experiments, and a linear regression line was calculated for the data points.
The concentration of ACV in the sample correlated highly with the reciprocal of the dilution of the endpoint. Endpoints did not deviate more than one dilution from the linear regression plot. By using this graph as a standard, it is possible to determine the concentration of ACV in an unknown sample, based on endpoints obtained in the assay.
Reconstruction assays. To ensure that deproteinization would not affect the concentration of ACV measured in plasma and urine samples, we performed reconstruction assays with plasma and urine samples containing concentrations of ACV ranging from 0 to 200 ,uM. The results for plasma samples were almost identical to those for maintenance medium, indicating that deproteinization did not interfere with recovery of acyclovir and that the plasma itself did not affect the assay (Fig. 3) . Figure 4 shows an analogous reconstruction experiment for urine samples. The plot is similar to that obtained for plasma and maintenance medium. Urine samples caused cellular toxicity in dilutions under 1/4. This finding proved to be of little practical consequence, because urine samples of patients receiving ACV contain very high concentrations of ACV.
These reconstruction assays indicate that the ACV in patient plasma and urine can be accurately measured by the virus inhibition assay after deproteinization. Furthermore, endpoints based on assays with known amounts of ACV in maintenance medium can be used to construct standard curves to be used in assays of plasma and urine.
Assay of samples from patients. The levels of ACV in plasma and urine samples of two patients receiving various doses of parenteral ACV were measured. Each study included a standard assay with known amounts of ACV in the maintenance medium. The endpoints of the standard assays were used to construct a curve analogous to that shown in Fig. 2 . Each patient sample was assayed in duplicate or triplicate, endpoints were matched to ACV concentrations by using the standard curve, and the results were averaged. Urine samples were diluted 10- fold because of the high concentrations of ACV present in the samples.
The urine and plasma levels of ACV in patients receiving doses of 500 mg/M2 (12 
DISCUSSION
Assay methods for detecting ACV in plasma samples include high-performance liquid chromatography (4) and RIA, with sensitivities of -1.0 and -0.1 ,M, respectively (12) . Both of these methods have limitations in clinical and research use. High-perfornance liquid chromatography is time consuming and requires expensive equipment, and specific rabbit anti-ACV antibody and radioactive-labeled ACV are necessary for the RIA (12) . In addition, these methods do not necessarily measure biologically active drugs.
The virus inhibition assay described here al- The assay is similar in principle to bioassay techniques previously described which measure the levels of adenine arabinoside and ribavirin (2, 14) . In contrast to adenine arabinoside, acyclovir has been shown to have minimal cleavage or metabolism in vivo (12) . This makes it possible to use the virus inhibition assay presented here with only simple preparation of samples.
This assay technique involves serial twofold dilutions of specimens from patients until an endpoint is reached, analogous to determining an antibody titer by using a complement fixation test which is accurate within one dilution of the endpoint. This potential variability of the test was reduced by including a standard curve of known ACV concentrations from 0 to 200 ,uM with each assay (Fig. 2) . Each sample was run in triplicate or duplicate to ensure an accurate endpoint determination, and the results were averaged.
The concentrations of ACV determined in samples from patients correlated well with the RIA results. The lower limit of sensitivity of our assay, approximately 1.0 ,uM, is higher than that of the RIA. Because of this, measurements of low levels of ACV should be more accurate if done by RIA. This difference in sensitivity caused a greater percentage of disagreement in values close to the lower limit of sensitivity of the virus inhibition assay.
Overall, the concentrations measured by the virus inhibition assay were 20% higher than those measured by RIA. The difference may be explained in part by a recent discovery that the specific antibody used in the RIA of these particular specimens may not measure both the free base of ACV and its sodium salt (M. Hintz, personal communication). This suggests that the true correlation of the techniques may be even closer than reported. In contrast to RIA and high-performance liquid chromatography, the virus inhibition assay measures the biological activity of ACV. The fact that ACV concentrations measured by RIA and the virus inhibition assay were similar indicates that the majority if not all of the ACV measured by RIA retained biological activity.
The lowest ACV concentration measurable by the assay is limited by the susceptibility of the virus to ACV. The HSV-1 strain used in this assay was inhibited by a relatively low concentration of ACV; however, it is possible that the use of a more susceptible HSV-1 strain or another cell line may increase the sensitivity of the assay. In addition, the assay can be adapted to a 24-h procedure with the use of an HSV-1 virus stock with a higher titer. This compares favorably with the 2 to 3 days required for obtaining results with the RIA technique.
This assay has proved to be reliable and clinically useful in following patients receiving parenteral acyclovir. The principle of this technique may also be applied to other antiviral agents for the study of pharinacokinetics.
